Odyssey Nets $279M in IPO After Second Attempt

By Grace Kim

Odyssey pulled in $279 million in its initial public offering — and it took two tries to get there. The biotechnology company returned to market after an earlier attempt fell short, according to BioPharma Dive.

The figure stands out. A $279 million raise is a sizable haul for a biotech IPO, and Odyssey secured it only after revisiting the public markets a second time.

What happened on the first try?

Odyssey's first attempt at going public did not close the deal. The company came back to market and, on this second run, completed the offering at $279 million, BioPharma Dive reports.

A retried IPO that lands a nine-figure sum signals real demand the second time around. Investors who passed once came back — or new ones stepped in.

Why does the number matter?

The $279 million total gives Odyssey fresh capital to fund its operations. For a biotech, that runway matters: drug development is expensive, and public markets have been selective about which companies they fund.

The successful second attempt also says something about timing. Companies that relaunch an IPO often reprice, restructure the offering, or wait for a friendlier market window before trying again.

What comes next?

With $279 million now banked, Odyssey faces the standard test of any newly public biotech: turning a one-time raise into durable progress before the capital runs out. How the company deploys the money will determine whether the second try was worth the wait.